标题：胰激肽原酶治疗糖尿病肾病疗效的系统评价

      作者：陈晓正，陈 曦，何健敏
    (韶关市铁路医院内二科，广东 韶关 512023)

      卷次： 2014年25卷1期

      【摘要】 目的 评价胰激肽原酶治疗糖尿病肾病的疗效。方法 通过检索近二十年 PubMed、Science
Direct、EBSCO Host、EMbase、The Cochrane Library、中国学术期刊全文数据库、万方数据库、维普中文科技期刊
全文数据库，对纳入研究的方法学进行评价。研究者对纳入文献的质量进行严格评价和资料提取，使用Review
manager 5.0软件对符合质量标准的RCTs行系统评价。结果 12个RCT共纳入762例患者，其中治疗组389例，
对照组373例，系统评价结果显示，相比于血管紧张素Ⅱ受体拮抗剂、血管紧张素转化酶抑制剂、前列地尔，采用
胰激肽原酶治疗糖尿病肾病，更能显著降低尿白蛋白排泄率，从而缓解糖尿病肾病的病理进程。结论 胰激肽
原酶可显著提升治疗糖尿病肾病的疗效，值得推广。

      【关键词】 胰激肽原酶；糖尿病肾病；尿白蛋白排泄率

      【中图分类号】 R587.2 【文献标识码】 A 【文章编号】 1003—6350（2014）01—0119—07


Clinical efficacy of Kininogenase in the treatment of diabetic nephropathy: a systematic evaluation.
CHEN
Xiao-zheng, CHEN Xi, HE Jian-min. Department of Internal Medicine, Shaoguan Railway Hospital, Shaoguan 512023,
Guangdong, CHINA

【Abstract】 Objective To evaluate the clinical efficacy of Kininogenase in the treatment of diabetic nephrop-
athy. Methods The methodology were evaluated based on references in the recent 20 years from PubMed, Science
Direct, EBSCO Host, EMBASE, The Cochrane Library, CNKI, CECDB CQVIP. The researchers performed rigorous
evaluation on the quality of the included studies and extracted data. The Review Manager 5.0 Software was used to
evaluate the qualified randomized controlled trials (RCTs). Results Twelve RCTs were included, involving 762 pa-
tients (389 cases of the treatment group and 373 cases of the control group). Compared to angiotensinⅡ receptor an-
tagonist (ARB), angiotensin converting enzyme inhibitors (ACEI), alprostadil, kininogenase can significantly reduce
the urinary albumin excretion rate in the treatment of diabetic nephropathy, thus alleviating the pathological process of
diabetic nephropathy. Conclusion Kininogenase has significant curative effect in the treatment of diabetic nephropa-
thy and is worthy of promotion.